Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 133

1.

Macular toxicity and blind spot enlargement during a treatment by voriconazole: A case report.

Mounier A, Agard E, Douma I, Chehab HE, Vie AL, Dot JM, Dot C.

Eur J Ophthalmol. 2018 Jul;28(4):NP11-NP14. doi: 10.1177/1120672117750051. Epub 2018 Apr 6.

PMID:
29623723
2.

A pediatric case of squamous cell cancer in situ in the setting of sclerodermatous graft-versus-host disease and voriconazole treatment.

Li AW, Lalor LE, Bellodi Schmidt F, Luu M.

Pediatr Dermatol. 2018 May;35(3):e165-e169. doi: 10.1111/pde.13473. Epub 2018 Mar 23.

PMID:
29570823
3.

Voriconazole therapeutic drug monitoring: Factors associated with supratherapeutic and subtherapeutic voriconazole concentrations.

You H, Dong Y, Zou Y, Zhang T, Lei J, Chen L, Wang X, Dong Y, Wang T.

Int J Clin Pharmacol Ther. 2018 May;56(5):239-246. doi: 10.5414/CP203184.

PMID:
29393850
4.

Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections.

Xing Y, Chen L, Feng Y, Zhou Y, Zhai Y, Lu J.

BMC Infect Dis. 2017 Dec 28;17(1):798. doi: 10.1186/s12879-017-2913-8.

5.

Novel fluconazole derivatives with promising antifungal activity.

Thamban Chandrika N, Shrestha SK, Ngo HX, Howard KC, Garneau-Tsodikova S.

Bioorg Med Chem. 2018 Feb 1;26(3):573-580. doi: 10.1016/j.bmc.2017.12.018. Epub 2017 Dec 17.

PMID:
29279242
6.

Efficacy and safety of voriconazole in immunocompromised patients: systematic review and meta-analysis.

Rosanova MT, Bes D, Serrano Aguilar P, Sberna N, Lede R.

Infect Dis (Lond). 2018 Jul;50(7):489-494. doi: 10.1080/23744235.2017.1418531. Epub 2017 Dec 20. Review.

PMID:
29262742
7.

Severe Hyperkalemia Complicating Voriconazole Treatment in a Kidney Transplant Recipient With Histoplasmosis: A Case Report.

Nazmul MN, Miles CD, Westphal SG.

Transplant Proc. 2017 Dec;49(10):2372-2373. doi: 10.1016/j.transproceed.2017.09.007.

PMID:
29198681
8.

Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study.

Hoenigl M, Prattes J, Neumeister P, Wölfler A, Krause R.

Mycoses. 2018 Mar;61(3):201-205. doi: 10.1111/myc.12727. Epub 2017 Nov 22.

9.

Longitudinal melanonychia due to voriconazole therapy during treatment of chromoblastomycosis.

Criado PR, Cosenza FD, Junior WB, Ferreira PS.

Clin Exp Dermatol. 2018 Jan;43(1):75-76. doi: 10.1111/ced.13279. Epub 2017 Oct 13. No abstract available.

PMID:
29030858
10.

Possible anti-depressant effect of efavirenz and pro-depressive-like effect of voriconazole in specified doses in various experimental models of depression in mice.

Patel TK, Patel VB, Rana DG.

Pharmacol Rep. 2017 Oct;69(5):1082-1087. doi: 10.1016/j.pharep.2017.04.018. Epub 2017 May 1.

PMID:
28986123
11.

Multi-azole-resistant strains of Cryptococcus neoformans var. grubii isolated from a FLZ-resistant strain by culturing in medium containing voriconazole.

Kano R, Okubo M, Hasegawa A, Kamata H.

Med Mycol. 2017 Nov 1;55(8):877-882. doi: 10.1093/mmy/myw101.

PMID:
28927230
12.

A cross-sectional survey of voriconazole prescribers: Assessing current practice and knowledge of cutaneous side effects.

Chansky PB, Wanat K, Pappas-Taffer L, Rosenbach M, Micheletti RG.

J Am Acad Dermatol. 2017 Oct;77(4):769-770. doi: 10.1016/j.jaad.2017.04.1136. No abstract available.

PMID:
28917461
13.

Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study.

Yi WM, Schoeppler KE, Jaeger J, Mueller SW, MacLaren R, Fish DN, Kiser TH.

Ann Clin Microbiol Antimicrob. 2017 Sep 11;16(1):60. doi: 10.1186/s12941-017-0235-8.

14.

Voriconazole-induced periostitis deformans: serial imaging in a patient with ANCA vasculitis.

Cormican S, Adams N, O'Connell P, McErlean A, de Freitas D.

Skeletal Radiol. 2018 Feb;47(2):191-194. doi: 10.1007/s00256-017-2764-9. Epub 2017 Sep 2. Erratum in: Skeletal Radiol. 2018 Jan 20;:.

PMID:
28866833
15.

Graded isavuconazole introduction in a patient with voriconazole allergy.

Morales MK, Harris C, Shoham S.

Transpl Infect Dis. 2017 Dec;19(6). doi: 10.1111/tid.12772. Epub 2017 Nov 3. Review.

PMID:
28851131
16.

Voriconazole-refractory invasive aspergillosis.

Park SY, Yoon JA, Kim SH.

Korean J Intern Med. 2017 Sep;32(5):805-812. doi: 10.3904/kjim.2017.109. Epub 2017 Aug 24. Review.

17.

Oxycodone-induced neurotoxicity secondary to concurrent voriconazole use in a patient with cancer.

Alghothani L, Gustin J.

J Opioid Manag. 2017 May/Jun;13(3):141-142. doi: 10.5055/jom.2017.0381.

PMID:
28829515
18.

Voriconazole Antifungal Prophylaxis in Children With Malignancies: A Nationwide Study.

Pana ZD, Kourti M, Vikelouda K, Vlahou A, Katzilakis N, Papageorgiou M, Doganis D, Petrikkos L, Paisiou A, Koliouskas D, Kattamis A, Stiakaki E, Chatzistilianou M, Vasilatou-Kosmidis H, Polychronopoulou S, Grafakos S, Roilides E.

J Pediatr Hematol Oncol. 2018 Jan;40(1):22-26. doi: 10.1097/MPH.0000000000000926.

PMID:
28816795
19.

Severe neurological disorders and refractory aspergillosis in an adolescent treated by vincristine and voriconazole.

Bennis Y, Bodeau S, Lutun A, Gourmel A, Solas C, Quaranta S, Guillaume N, Chouaki T, Lemaire-Hurtel AS, Masmoudi K.

J Clin Pharm Ther. 2018 Apr;43(2):265-268. doi: 10.1111/jcpt.12603. Epub 2017 Aug 10.

PMID:
28795412
20.

Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.

Hachem R, Assaf A, Numan Y, Shah P, Jiang Y, Chaftari AM, Raad II.

Int J Antimicrob Agents. 2017 Sep;50(3):384-388. doi: 10.1016/j.ijantimicag.2017.03.021. Epub 2017 Jul 8.

PMID:
28694233

Supplemental Content

Loading ...
Support Center